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INTRODUCTION
Spinal cord injury (SCI) which is one of the most
dangerous nervous system disorders, commonly aﬀects
younger population, and causes persistent and long-
term disabilities. Unfortunately, about 90% of the
patients suﬀer from long-term motor dysfunctions and
approximately 78% experience moderate to severe pain.
SCI and its complications impose great direct and
indirect ﬁnancial burdens; the annual treatment cost for
each patient is estimated to be 26,270 dollars (Mann
et al., 2013).
SCI is regarded as one of the main causes of motor
dysfunction and neuropathic pain. There is no cure for it
and most of the therapeutic modalities are only
symptomatic (Finnerup, 2013; Sharp et al., 2012; Kumru
et al., 2013; Nasirinezhad et al., 2015b). Pharmacother-
apy holds the base of current treatment with little inﬂu-
ence on functional recovery with only 30–40% decrease
in neuropathic pain symptoms (Finnerup et al., 2005;
Backonja et al., 2006). Besides, numerous medication
adverse side eﬀects are the major obstacles for the
long-term use (Marineo et al., 2012; Hosseini et al.,
2014; Nasirinezhad et al., 2015a). Motor dysfunction
and neuropathic pain will persist unless the injured region
recovers or pain control pathways reinforce. However,
neurogenesis rarely occurs in central nervous system
and self-healing in injured cells is rather limited. Accord-
ingly, researchers are investigating to ﬁnd methods to
improve cell restoration. Currently, cell transplantation is
considered as an appropriate choice for treating SCIs.
According to the recent studies, cell therapy can create
new neural connections which would then lead to neuro-
pathic pain alleviation and improved functional recovery
(Guenot et al., 2007; Hama and Sagen, 2007).
Various cell populations can be used for SCI
treatment. Survival and diﬀerentiation of the
transplanted cells are mainly inﬂuenced by host-related
factors as well as innate properties. For instance,
having been injected in brain neurogenic regions, such
as the hippocampus or sub-ventricular zones, neural
stem/progenitor cells (NSPCs) exhibit acceptable
diﬀerentiation (Sun et al., 2011); but when transplanted
in other parts of the nervous system, low survival and dif-
ferentiation are observed (Mark Richardson et al., 2005).
Panel 1. Keywords used for search in MEDLINE and EMBASE
databases
Database Search terms
Medline (PubMed) ‘‘Neural stem cells”[MeSH] OR
(Progenitor cell*[tiab] OR Neural
progenitor stem cell*[tiab] OR Neural
precursor cell*[tiab] OR Spinal cord stem
cell*[tiab] OR Brain stem cell*[tiab] OR
Brain derived stem cell*[tiab] OR Spinal
derived stem cell*[tiab] OR Embryonic-
derived neural stem cell*[tiab] OR
Embryonic neural stem cel*l[tiab] OR
Induced pluripotent stem cell*[tiab] OR
NSC[tiab] OR NSPC[tiab]) AND ‘‘Spinal
cord injuries”[MeSH] OR (Spinal cord
contusion[tiab] OR Spinal cord transection
[tiab] OR Injured spinal cord[tiab] OR
Spinal Cord Traum*[tiab] OR Spinal cord
Hemisection[tiab] OR Spinal compression
[tiab] OR Traumatic Myelopath*[tiab] OR
Spinal Cord Laceratio*[tiab] OR Post-
Traumatic Myelopath*[tiab])
EMBASE (OvidSP) exp Neural Stem Cells/ or (Neural Stem
Cells or Progenitor cells or Neural
progenitor stem cell or Neural precursor
cell or Embryonic-derived neural stem cell
or Embryonic neural stem cell or Induced
pluripotent stem cell$ or NSC or NSPC).ti,
ab. and exp Spinal cord injuries/ or (Spinal
cord injur$ or Spinal cord contusion or
Spinal cord transection or Injured spinal
cord or Spinal Cord Traum$ or Spinal cord
Hemisection or Spinal compression or
Traumatic Myelopath$ or Spinal Cord
Laceration or Post-Traumatic Myelopath
$).ti,ab.
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transplanted cell outcome is determined by innate charac-
teristics and transplantation location.
Studies have shown that NSPCs are subject to renewal
and can produce main neural cell phenotypes (neurons,
oligodendrocytes and astrocytes) after transplantation in
injured spinal cord (Tarasenko et al., 2007). These cells
can also modulate immune and inﬂammatory responses
(Lee et al., 2008a; Bacigaluppi et al., 2009; Ottoboni
et al., 2015). Hence, as proposed bymany studies, NSPCs
may be the best choice in transplantation treatment for
physiologic repair of the lesion, functional recovery and
neuropathic pain relief in patients with SCIs (Bottai et al.,
2008; Abematsu et al., 2010; Amemori et al., 2013). On
the other hand, some researchers believe that these cells
are not signiﬁcantly eﬀective in spinal lesion treatment
(Macias et al., 2006; Nutt et al., 2013). These discrepan-
cies might be due to the diﬀerences in treatment protocols,
number of transplanted cells, application of co-treatments,
source of extracted cells, and etc. In this regard, a system-
atic review showed that no consensus has been reached
on the optimal source of NSPCs and their application in
various models of spinal cord injuries, severity of injuries,
and treatment protocol (Tetzlaﬀ et al., 2011).
So, there is no reliable and comprehensive review to
judge whether NSPC transplantation is really a suitable
therapeutic protocol for SCIs. Conceivably, a meta-
analysis seems to be an appropriate alternative solution
for this problem. Recently, few meta-analyses were
performed on the subject but none evaluated neural
stem cells. In the previous meta-analysis we showed
that bone marrow-derived mesenchymal stem cell
application improved mechanical allodynia but had no
signiﬁcant eﬀects on hyperalgesia (Hosseini et al.,
2015). Accordingly, this study aimed to conduct a system-
atic review and meta-analysis to assess the eﬃcacy of
NSPCs on functional recovery and neuropathic pain relief
in animal models of SCI.METHODS
Search strategy
Two independent reviewers carried out an extended
search in electronic databases of Medline (via PubMed),
EMBASE (via OvidSP), CENTRAL, SCOPUS, Web of
Science (BIOSIS), and ProQuest ﬁnding papers
published until the end of December, 2015. Search
strategy was based on keywords related to ‘‘neural stem
cells", ‘‘neural progenitor stem cell” and ‘‘neural
precursor cell” in combination with terms related to
‘‘spinal cord injuries". The combined terms in two
databases of Medline and EMBASE are presented in
Panel 1. In order to prevent omission of related studies,
keywords were chosen as extensive as possible.
Keywords were extracted from Mesh, EMTREE, and via
manual search in titles and abstracts of the articles.
Additionally, PubMed search was not limited to
Medline. Archived articles in PubMed Central were also
screened. In order to further include non-indexed
reports, search was also conducted in Google search
engine and Google Scholar. Two strategies werepursued to gather gray literature: (a) authors of related
articles were contacted via email to ask for unpublished
data or dissertations and unrecorded data, (b) ProQuest
database was meticulously searched for related
dissertations. In cases where the article was not
available online, the author was contacted. If there were
no answers, a reminder was sent to the author, one
week later. In case of no reply, other authors of the
article were contacted through social networks including
ResearchGate and LinkedIn, asking for the data. Two
studies were obtained using this method.
To ﬁnd additional articles, hand-search was
performed in the bibliographies of relevant studies which
yielded inclusion of two more articles. Moreover, journal
hand-searching was also carried out. To do so,
gathered studies were entered the EndNote X7 software
and a list of highly focused journals with the highest
number of articles on the subjects of stem cell therapy,
neuroscience and spine was provided. All issues of the
selected journals were manually screened and three
more articles added to this strategy.
Inclusion criteria
In the present survey, all controlled studies evaluating
neural stem cell eﬀects on functional recovery and
sensory improvement after SCIs were included. No
M. Youseﬁfard et al. / Neuroscience 322 (2016) 377–397 379temporal or linguistic restrictions were considered.
Included studies were in vivo animal models (non-
human), in which SCI was induced through compression,
contusion, hemisection or transection models with no
age, gender or phylum restrictions. A four-week gap
during the follow up period was considered as exclusion
criterion, since the minimum amount of time needed for
the cell therapy eﬀects on functional recovery and
sensory improvement is three to four weeks. Surveys
lacking control groups (sham, saline-treated or vehicle
treated groups) were also excluded.Quality assessment and data extraction
Duplicate articles were removed using EndNote software
(version X7, Thomson Reuters, 2011). Two of the authors
(M.Y and S.S) independently examined the titles and
abstracts of the articles and screened potentially eligible
studies. Then, study full-texts were investigated and
surveys met with the inclusion criteria were selected.
Data extraction performed by researchers blinded to the
author, journal and organization of the studies. Data
recorded in a checklist designed based on PRISMA
statement guidelines (Moher et al., 2009). The data
included: (i) animal characteristics (number, recipient spe-
cies, gender, weight), (ii) SCI model details including
injury model, severity and location, (iii) cell therapy proto-
col as time interval between injury and treatment, delivery
route, antibiotics application and immunosuppressive
agents use, transplanted cell count, (iv) graft type (allo-
geneic or xenogeneic), (v) extracted neural stem cells
characteristics including donor species, embryonic or
adult source, (vi) follow-up duration (vii) outcome (motor
function and neuropathic pain symptoms), and (viii) prob-
able biases. Reviewers’ disagreements were discussed
with a third reviewer and settled through mutual coopera-
tion (93% agreement). For quality assessment, each
study was assigned a score of good, fair or poor, based
on a 19-item checklist recommendation of Antonic et al.
(Antonic et al., 2013) and Hassannejad et al.
(Hassannejad et al., 2015) studies.Data synthesis
Outcomes assessed included functional recovery and
neuropathic pain symptoms (allodynia and hyperalgesia).
Data were recorded as mean and standard error. In case
data were presented as charts, the data extraction
method proposed by Sistrom and Mergo was utilized
(Sistrom and Mergo, 2000). When outcomes were
reported in multiple stages of the survey, only the last
reported ﬁgures were included. If multiple reports were
given for the same population, the study with the largest
sample size and the longest follow-up period would be
included. In non-extracted data studies, the author was
contacted and asked for the required information.Statistical analysis
Data were summarized and entered in the STATA 11.0
statistical software in mean and standard deviation
formats. In case standard errors were presented,standard deviations were calculated according to the
study sample size. For each individual comparison,
based on Hedges’ g, a standardized mean diﬀerence
(SMD) was calculated with a conﬁdence interval of 95%
(95% CI) and then a pooled eﬀect size was presented.
Publication bias was examined through Egger’s and
Begg’s tests and funnel plots drawing (Egger et al.,
1997). Heterogeneity was assessed using Chi-squared
and I2 tests. A p value of 0.1 or less and an I2 greater than
50%were considered as existence of heterogeneity. Fixed
eﬀect model was used for homogenous studies, and if the
positive heterogeneity held, subgroup analysis was per-
formed to determine its source. Random eﬀects model
was ﬁtted for cases of unidentiﬁed heterogeneity source.
Subgroup analysis was carried out based on animal
gender, recipient species (mice, rat, and so), injury model
(contusion, compression, hemisection, transection), loca-
tion (cervical, thoracic, lumbar), and severity (moderate,
severe), stem cell origin (brain, spine, other), intervention
phase (acute, sub-acute, chronic), delivery route (intra
spinal and so), graft type (allogeneic, xenogeneic), stem
cell type (wild type NSPC; induced pluripotent stem
cell-derived NSPC), number of transplanted cells, donor
species (mice, rat, human, other), and age range (fetal,
newborn, adult), co-treatment use, antibiotic, or immuno-
suppressiveagents, observer neutrality, and follow-upperiod
(less than 8 weeks, equal to, or more than 8 weeks). Eight
weeks follow up was set based on the functional recovery
duration in which plateau is being reached. It is worth men-
tioning that meta-analyses were carried out only if the data
were reported by at least three studies.RESULTS
Characteristics of the included studies
Search in electronic sources yielded 10,153 non-
duplicated studies. Screening through titles and
abstracts found 298 articles, 81 of which met the
inclusion criteria. A total of 74 studies were included in
the meta-analysis at last (Teng et al., 2002; Cummings
et al., 2005; Hofstetter et al., 2005; Iwanami et al.,
2005; Okada et al., 2005; Pallini et al., 2005; Karimi-
Abdolrezaee et al., 2006, 2010; Macias et al., 2006; Ziv
et al., 2006; Guo et al., 2007, 2012; Parr et al., 2007,
2008a,b; Tarasenko et al., 2007; Zhang et al., 2007;
Bottai et al., 2008; Lowry et al., 2008; Pan et al., 2008;
Hooshmand et al., 2009; Kumagai et al., 2009; Lee
et al., 2009; Abematsu et al., 2010; Chen et al., 2010;
Hu et al., 2010; Johnson et al., 2010; Salazar et al.,
2010; Tsuji et al., 2010; Yamane et al., 2010; Du et al.,
2011; Kim et al., 2011, 2012; Nori et al., 2011; Wang
et al., 2011, 2014; Xu et al., 2011; Yasuda et al., 2011;
Cheng et al., 2012; Cusimano et al., 2012; Fujimoto
et al., 2012; Gu et al., 2012; Kobayashi et al., 2012; Lu
et al., 2012, 2014; Amemori et al., 2013, 2015; He
et al., 2013; Kumamaru et al., 2013; Luo et al., 2013;
Nishimura et al., 2013; Nutt et al., 2013; Park et al.,
2013; Piltti et al., 2013a,b; Sontag et al., 2013; van
Gorp et al., 2013; Xia et al., 2013; Yang et al., 2013;
Hong et al., 2014; Hwang et al., 2014; Iwasaki et al.,
2014; Nemati et al., 2014; Ormond et al., 2014;
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et al., 2015; Pomeshchik et al., 2015; Romanyuk et al.,
2015; Salewski et al., 2015a,b; Yao et al., 2015; Yokota
et al., 2015). Search ﬂowchart and selection methods
are presented in Fig. 1. These studies comprised 125
separate experiments whose data were included in the
ﬁnal analysis. In 60 studies, subject motor function was
only evaluated (Cummings et al., 2005; Iwanami et al.,
2005; Okada et al., 2005; Pallini et al., 2005; Ziv et al.,
2006; Guo et al., 2007, 2012; Parr et al., 2007, 2008a,b;
Tarasenko et al., 2007; Zhang et al., 2007; Bottai et al.,
2008; Lowry et al., 2008; Pan et al., 2008; Hooshmand
et al., 2009; Kumagai et al., 2009; Lee et al., 2009;
Abematsu et al., 2010; Chen et al., 2010; Johnson
et al., 2010; Tsuji et al., 2010; Yamane et al., 2010; Du
et al., 2011; Kim et al., 2011, 2012; Nori et al., 2011;
Wang et al., 2011, 2014; Xu et al., 2011; Yasuda et al.,
2011; Cheng et al., 2012; Cusimano et al., 2012;
Fujimoto et al., 2012; Gu et al., 2012; Kobayashi et al.,
2012; Lu et al., 2012, 2014; Amemori et al., 2013, 2015;
He et al., 2013; Kumamaru et al., 2013; Nishimura
et al., 2013; Nutt et al., 2013; Park et al., 2013; Xia
et al., 2013; Yang et al., 2013; Hong et al., 2014;
Hwang et al., 2014; Iwasaki et al., 2014; Nemati et al.,
2014; Ormond et al., 2014; Sharp et al., 2014; Yuan
et al., 2014; Iwai et al., 2015; Liu et al., 2015;
Pomeshchik et al., 2015; Romanyuk et al., 2015; Yokota
et al., 2015; Salewski et al., 2015a) and in ﬁve just sen-
sory status was assessed (Hu et al., 2010; Luo et al.,
2013; Piltti et al., 2013a,b; Yao et al., 2015). These ele-
ments were both simultaneously assessed in 10 surveysFig. 1. Flowchart of including stu(Teng et al., 2002; Hofstetter et al., 2005; Karimi-
Abdolrezaee et al., 2006, 2010; Macias et al., 2006;
Salazar et al., 2010; Sontag et al., 2013; van Gorp et al.,
2013; Amemori et al., 2015; Salewski et al., 2015b). Char-
acteristics of the included studies are presented in Table 1.
Gathered data from 2537 animals (1204 in control
group and 1333 in the treatment group) were pooled
and analyzed together. Evaluation was conducted on
101 female and 24 male experimental animals.
Contusion model was the most commonly used SCI
induction model performed on 68 experiments, followed
by 24 transection, 15 clip compression, 14 hemisection,
and four balloon compression experiments. Experiment-
induced injuries were severe in half and moderate in the
other half. Mean time interval between injury and
treatment was 9.3 ± 11.3 days (ranged from 1 to
56 days). In 40 experiments transplantation was
performed right after injury induction (acute phase), in
74 procedures were 3–10 days apart (sub-acute phase),
and in 11 this gap was equal to or more than two weeks
(chronic phase). Intra-spinal transplantation was carried
out in 114 experiments. Graft type was allogeneic in 77
experiments. The number of transplanted cells ranged
from 1  105 to 4  107 cells per kilograms of the
animals’ body weight. Quality assessment of the
included studies is presented in Table 2.
Meta-analysisEﬃcacy of neural stem cell transplantation on func-
tional recovery. In literature review, 69 studies includingdies in the meta-analysis.
Table 1. Characteristics of included studies
Author, Year Gender/Species/Weight
(gr)
Model/Location of injury/Severity Cell source/Donor/Graft/Dose/Type/Intervention time
(day)
Immunosuppressive/
Antibiotic/Blinding
Follow up
(week)
Abematsu et al., 2010 Male/Mice/37–45 Contusion/T9–T10/Severe Brain/Fetus/Mice/IS/1  106/Allogeneic/7 Yes/Yes/Yes 8
Amemori et al., 2013 Male/Rat/270–300 Balloon compression/T8–T9/
Moderate
Spine/Fetus/Human/IS/5  105/Xenogeneic/7 Yes/Yes/Yes 8
Amemori et al., 2015 Male/Rat/270–300 Balloon compression/T8/Moderate Lung/Fetus/Human/IS and IT/5  105/Xenogeneic/7 Yes/Yes/Yes 8
Bottai et al., 2008 Male/Mice/29–30 Contusion/T8/Moderate Brain/Adult/Mice/IS/1  106/Allogeneic/1 No/No/Yes 8
Chen et al., 2010 Female/Rat/250–300 Hemisection/T9/Severe Spine/Fetus/Rat/IS/2  105/Allogeneic/1 No/No/Yes 24
Cheng et al., 2012 Female/Rat/200–350 Contusion/T10/Moderate Brain/Fetus/Human/IT/5  105/Xenogeneic/1 No/Yes/Yes 7
Cummings et al., 2005 Female/Mice/18–22 Contusion/T8/Moderate Brain/Fetus/Human/IS/7.5  104/Xenogeneic/9 No/No/Yes 16
Cusimano et al., 2012 Male/Mice/20–22 Contusion/T11/Severe Brain/Adult/Mice/IS/7.5  104 or 1.5  105/Allogeneic/7
or 21
No/Yes/Yes 8
Du et al., 2011 Female/Rat/220–250 Transection/T10/Severe Brain/Newborn/Rat/IS/1.5  105/Allogeneic/1 No/Yes/Yes 8
Fujimoto et al., 2012 Female/Mice/18–20 Contusion/T10/Moderate Skin ﬁbroblast/Adult/Human/IS/5  105/Xenogeneic/7 No/Yes/Yes 9
Gu et al., 2012 Male/Rat/200–250 Transection/T10/Severe Brain/Fetus/Mice/IS/2  104/Xenogeneic/1 No/No/No 4
Guo et al., 2007 Female/Rat/200–220 Transection/T9–T10/Severe Brain/Newborn/Rat/IS/4  106/Allogeneic/1 No/Yes/No 8
Guo et al., 2012 Female/Rat/200–300 Transection/T8/Severe Brain/Adult/Rat/IS/1.5  106/Allogeneic/1 Yes/Yes/Yes 12
He et al., 2013 Male/Rat/200–250 Transection/T10/Severe Brain/Fetus/Mice/IS/3  105/Xenogeneic/1 No/No/Yes 4
Hofstetter et al., 2005 Female/Rat/250 Contusion/T8–T9/Moderate Brain/Adult/Rat/IS/1  105/Allogeneic/7 No/No/Yes 9
Hong et al., 2014 Female/rat/230–250 Contusion/T8–T9/Moderate Embryonic ﬁbroblasts/Fetus/Mice/IS/1  106/
Xenogeneic/9
Yes/No/Yes 12
Hooshmand et al., 2009 Female/Mice/17–20 Contusion/T8/Moderate Brain/Fetus/Human/IS/7.5  104/Xenogeneic/9 Yes/No/Yes 16
Hu et al., 2010 Female/Mice/20–22 Contusion/T8/Moderate Whisker follicle/Adult/Mice/IS/1.4  105/Allogeneic/1 No/No/No 4
Hwang et al., 2014 Male/Rat/250–300 Contusion/T9/Severe Spine/Fetus/Rat/IS/1  105/Allogeneic/7 No/No/Yes 7
Iwai et al., 2015 Female/Marmoset/300–
350
Contusion/C5/Severe Brain/Fetus/Marmoset/IS/1  106/Allogeneic/14 Yes/Yes/No 12
Iwanami et al., 2005 Female/Marmoset/280–
350
Contusion/C5/Severe Brain/Fetus/Human/IS/1  106/Xenogeneic/9 Yes/Yes/No 8
Iwasaki et al., 2014 Female/Rat/250 Compression/C6–C7/Moderate Brain/Adult/Mice/IS/4  105/Xenogeneic/14 Yes/Yes/Yes 10
Johnson et al., 2010 Female/Rat/250–275 Hemisection/T9/Severe Brain/Fetus/Mice/IS/1  105/Xenogeneic/14 Yes/Yes/Yes 8
Karimi-Abdolrezaee et al.,
2010
Female/Rat/250 Compression/T7/Moderate Brain/Adult/Mice/IS/4  105/Xenogeneic/49 Yes/Yes/Yes 9
Karimi-Abdolrezaee et al.,
2006
Female/Rat/250 Compression/T6–T8/Moderate Brain/Adult/Mice/IS/3–4  105/Xenogeneic/14 Yes/No/Yes 6
Kim et al., 2011 Female/Rat/250–300 Transection/T8/Severe Brain/Adult/Rat/IS/2.5  105/Allogeneic/1 Yes/No/Yes 6
Kim et al., 2012 Male/Rat/250 Compression/T9/Moderate Brain/Fetus/Mice/IS/3  105/Xenogeneic/1 Yes/No/Yes 6
Kobayashi et al., 2012 Female/Marmoset/300 Contusion/C5/Severe Skin ﬁbroblast/Adult/Human/IS/1  106/Xenogeneic/9 Yes/Yes/Yes 11
Kumagai et al., 2009 Female/Mice/20–22 Contusion/T10/Moderate Brain/Fetus/Mice/IS/5  105/Allogeneic/9 No/No/Yes 6
Kumamaru et al., 2013 Female/Mice/20–30 Contusion/T10/Moderate Spine/Fetus/Mice/IS/5  105/Allogeneic/1 or 7 or 13 No/No/Yes 6
Lee et al., 2009 / dogs/25,000–32,000 Hemisection/L2/Severe Brain/Fetus/Human/IS/1  107/Xenogeneic/1 No/Yes/Yes 12
Liu et al., 2015 Female/Rat/220–250 Transection/T10/Severe Embryonic ﬁbroblast/ Fetus/Mice/IS/1  106/
Xenogeneic/1
Yes/Yes/Yes 10
Lowry et al., 2008 Female/Mice/10_12 Hemisection/T8–T9/Severe Spine/Fetus/Mice/IS/1  105/Allogeneic/1 No/No/Yes 4
Lu et al., 2012 Female/Rat/160–200 Transection/T3/Severe Spine/Fetus/Rat and Human/IS/1.4  106/Xenogeneic/7
and 14
No/No/Yes 6
Lu et al., 2014 Female/Rat/160–200 Hemisection/C5/Severe Skin/Adult/Human/IS/1.4  106/Xenogeneic/14 No/No/Yes 12
Luo et al., 2013 Female/Rat/180–250 Transection/T7–T9/Severe Brain/Adult/Rat/IS/3  105/Allogeneic/1 Yes/Yes/Yes 4
(continued on next page)
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Table 1 (continued)
Author, Year Gender/Species/Weight
(gr)
Model/Location of injury/Severity Cell source/Donor/Graft/Dose/Type/Intervention time
(day)
Immunosuppressive/
Antibiotic/Blinding
Follow up
(week)
Macias et al., 2006 Female/Rat/200–250 Contusion/T8/Moderate Brain/Newborn/Mice/IS/1  105/Xenogeneic/8 Yes/Yes/Yes 4
Nemati et al., 2014 Male/monkeys/3000–
6000
Contusion/T9–T10/Moderate Brain/Adult/Monkey/IS/3–6  106/Allogeneic/10 Yes/Yes/Yes 26
Nishimura et al., 2013 Female/Mice/18–22 Contusion/T10/Moderate Brain/Fetus/Mice/IS/5  105/Allogeneic/9 or 42 No/No/Yes 6
Nori et al., 2011 Female/mice/20–22 Contusion/T10/Moderate Skin ﬁbroblast/Adult/Human/IS/5  105/Xenogeneic/9 No/No/Yes 7
Nutt et al., 2013 Female/Rat/180–230 Contusion/C4/Moderate Lung/Adult/Human/IS/2  105/Xenogeneic/28 Yes/No/Yes 8
Okada et al., 2005 Female/Mice/20–22 Contusion/T10/Moderate Brain/Fetus/Mice/IS/5  105/Allogeneic/1 or 7 No/No/No 6
Ormond et al., 2014 Female/Rat/200–250 Contusion/T9–T10/Moderate or
Severe
Brain/Adult/Rat/IS/1  106/Allogeneic/7 No/No/Yes 5
Pallini et al., 2005 Female/Mice/27–30 Transection/T7–T8/Severe Brain/Fetus/Mice/IS/1  105/Allogeneic/1 No/No/No 12
Pan et al., 2008 Female/Rat/250–300 Transection/T8–T9/Severe Brain/Fetus/Rat/IS/5  106/Allogeneic/1 No/Yes/Yes 12
Park et al., 2013 Female/Rat/250–300 Contusion/T10/Moderate Brain/Fetus/Human/IS/5  105/Xenogeneic/7 No/No/Yes 6
Parr et al., 2008a Female/Rat/250–300 Compression/T8–T9/Moderate Brain/Adult/Rat/IS/2  105 or 1.25  105/Allogeneic/9 Yes/No/Yes 14
Parr et al., 2008b Female/Rat/250–300 Compression/T8–T9/Moderate Brain/Adult/Rat/IS/2  105 or 1.25  105/Allogeneic/9 Yes/No/Yes 12
Parr et al., 2007 Female/Rat/250–300 Compression/T8–T9/Moderate Spine/Adult/Rat/IS/1  105/Allogeneic/1 Yes/No/Yes 16
Piltti et al., 2013a Female/Rat/180–200 Contusion/T9/Severe Brain/Fetus/Human/IS/2  105/Xenogeneic/9 Yes/Yes/Yes 13
Piltti et al., 2013b Female/Rat/180–200 Contusion/T9/Severe Brain/Fetus/Human/IS/2  105/Xenogeneic/9 Yes/Yes/Yes 13
Pomeshchik et al., 2015 Female/Mice/18–23 Contusion/T10/Moderate Skin/Adult/Human/IS/4  105/Xenogeneic/7 Yes/No/Yes 5
Romanyuk et al., 2015 Male/Rat/270–300 Balloon compression/T8–T9/
Moderate
Lung/Fetus/Human/IS/5  105/Xenogeneic/7 Yes/Yes/Yes 8
Salazar et al., 2010 Female/Mice/15–20 Contusion/T9/Moderate Brain/Fetus/Human/IS/7.5  104/Xenogeneic/30 No/Yes/Yes 16
Salewski et al., 2015a Female/Mice/15–20 Compression/T6–T8/Moderate Brain/Fetus/Human/IS/2  105/Allogeneic/7 Yes/No/Yes 8
Salewski et al., 2015b Female/Mice/15–20 Compression/T6–T8/Moderate Embryonic ﬁbroblast/Fetus/Human/IS/2  105/
Allogeneic/7
Yes/No/Yes 8
Sharp et al., 2014 Female/Rat/145–160 Transection/T3/Severe Brain/Fetus/Rat/IS/1.5  106/Allogeneic/14 No/Yes/Yes 7
Sontag et al., 2013 Female/m/20–25 Contusion/T9/Moderate Brain/Fetus/Human/IS/7.5  105/Xenogeneic/9 Yes/No/Yes 10
Tarasenko et al., 2007 Male/Rat/230–340 Contusion/T10/Moderate Brain/Fetus/Human/IS/1  105/Xenogeneic/9 Yes/Yes/Yes 12
Teng et al., 2002 Female/Rat/280–330 Hemisection/T9–T10/Severe Brain/Newborn/Murine/IS/1  105/Xenogeneic/1 No/No/Yes 10
Tsuji et al., 2010 Female/Mice/20–22 Contusion/T10/Moderate Embryonic stem cell/Fetus/Mice/IS/5  105/Allogeneic/9 No/No/Yes 5
van Gorp et al., 2013 Female/Rat/200–250 Compression/L3/Moderate Spine/Fetus/Human/IS/1.2  105/Xenogeneic/3 Yes/Yes/Yes 8
Wang et al., 2014 Female/Rat/220–250 Transection/T10/Severe Brain/Fetus/Rat/IS/1  106/Allogeneic/1 No/Yes/Yes 4
Wang et al., 2011 Female/Rat/220–250 Transection/T10/Severe Brain/newborn/Rat/IS/1  106/Allogeneic/1 No/Yes/Yes 8
Xia et al., 2013 Female/Rat/200–300 Hemisection/T8/Severe Spine/Fetus/Rat/IS/5  105/Allogeneic/1 No/Yes/Yes 24
Xu et al., 2011 Female/Rat/200 Contusion/T9/Moderate Brain/Fetus/Rat/IS/5  105/Allogeneic/56 No/Yes/Yes 8
Yamane et al., 2010 Female/Marmoset/280–
350
Contusion/C5/Moderate Brain/Fetus/Human/IS/1  106/Xenogeneic/9 Yes/Yes/Yes 12
Yang et al., 2013 Male/Rat/300–350 Contusion/T9–T10/Moderate Brain/Fetus/Porcine/IS/1  105/Xenogeneic/7 No/No/No 24
Yao et al., 2015 Male/Rat/200–220 Transection/T10/Severe Brain/Fetus/Mice/IS/3  106/Xenogeneic/1 No/Yes/No 5
Yasuda et al., 2011 Female/Mice/20–22 Contusion/T10/Moderate Brain/Fetus/Mice/IS/5  105/Allogeneic/9 No/No/Yes 6
Yokota et al., 2015 Female/Mice/20–22 Contusion/T8/Moderate or Severe Brain/Fetus/Mice/IS/5  105/Allogeneic/9 No/No/No 6
Yuan et al., 2014 Female/Rat/250–300 Hemisection/T9–T10/Severe Brain/Newborn/Mice/IS/1  107/Allogeneic/1 No/No/No 4
Zhang et al., 2007 Female/Rat/200–250 Transection/T10/Severe Brain/Newborn/Rat/IS/1  106/Allogeneic/1 No/Yes/No 8
Ziv et al., 2006 Female/Mice/20–22 Contusion/T12/Severe Brain/Fetus/Mice/ICV/5  105/Allogeneic/7 No/No/Yes 4
IS: intra-spinal; IT: intrathecal; ICV: intra cerebroventricular; T: thoracic level of spinal cord; C: cervical level spinal cord; L: lumbar level of spinal cord.
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transplantation on functional recovery of subjects after
SCI (Cummings et al., 2005; Iwanami et al., 2005;
Okada et al., 2005; Pallini et al., 2005; Ziv et al., 2006;
Guo et al., 2007, 2012; Parr et al., 2007, 2008a,b;
Tarasenko et al., 2007; Zhang et al., 2007; Bottai et al.,
2008; Lowry et al., 2008; Pan et al., 2008; Hooshmand
et al., 2009; Kumagai et al., 2009; Lee et al., 2009;
Abematsu et al., 2010; Chen et al., 2010; Johnson
et al., 2010; Tsuji et al., 2010; Yamane et al., 2010; Du
et al., 2011; Kim et al., 2011, 2012; Nori et al., 2011;
Wang et al., 2011, 2014; Xu et al., 2011; Yasuda et al.,
2011; Cheng et al., 2012; Cusimano et al., 2012;
Fujimoto et al., 2012; Gu et al., 2012; Kobayashi et al.,
2012; Lu et al., 2012, 2014; Amemori et al., 2013, 2015;
He et al., 2013; Kumamaru et al., 2013; Nishimura
et al., 2013; Nutt et al., 2013; Park et al., 2013; Xia
et al., 2013; Yang et al., 2013; Hong et al., 2014;
Hwang et al., 2014; Iwasaki et al., 2014; Nemati et al.,
2014; Ormond et al., 2014; Sharp et al., 2014; Yuan
et al., 2014; Iwai et al., 2015; Liu et al., 2015;
Pomeshchik et al., 2015; Romanyuk et al., 2015; Yokota
et al., 2015; Salewski et al., 2015a). Findings of this sec-
tion are presented in Fig. 2. Transplantation of these cells
signiﬁcantly improved restoration of motor function in the
subjects (Pooled SMD= 1.45; 95% CI: 1.23–1.67;
p< 0.001; I2 = 81.0%). Publication bias was not
observed in this part of the study (Coeﬃcient = 1.30;
95% CI: 0.49 to 3.09; p= 0.15). Due to a considerable
heterogeneity (I2 = 81.1%; p< 0.001), subgroup analy-
sis was performed. According to the ﬁndings presented
in Table 3, injury model, intervention phase, transplanted
cells numbers, and immunosuppressive administration
were found to be the main sources of heterogeneity. Cell
eﬃcacy considerably dropped (SMD= 0.58; 95% CI:
0.16–0.99) when cells were used in clip compression
induced SCIs model compared to transection
(SMD= 2.18; 95% CI: 1.45–2.93) model. Moreover, this
treatment improved motor function recovery to a greater
extent when cells were transplanted in acute
(SMD= 1.80; 95% CI: 1.36–2.24) or sub-acute
(SMD= 1.38; 95% CI: 1.08–1.67) phases compared to
the chronic phase (SMD= 1.04; 95% CI: 0.47–1.60)
(p= 0.03). Findings also showed better functional recov-
ery where more than 3  106 cell dose/kg was trans-
planted (SMD= 1.74; 95% CI: 1.43–2.05) compared
lower doses injection (SMD= 0.94; 95% CI: 0.67–1.22).
Immunosuppressive administration provoked signiﬁcantly
lower eﬃcacies (SMD= 0.87; 95% CI: 0.57–1.17).
In addition, co-treatment with growth factors
(SMD= 0.93; 95% CI: 0.22 to 2.08) and Schwann
cells or bone marrow-derived mesenchymal cells
(SMD= 1.21; 95% CI: 0.24 to 2.65) hindered neural
stem cells eﬀects, while scaﬀold application
(SMD= 2.19; 95% CI: 1.30–2.07) improved cells
eﬃcacy. Motor function recovery was also found to be
lower when cells were transplanted in cervical injuries
(SMD= 0.54; 95% CI: 0.05–1.03) compared to thoracic
injuries (SMD= 1.52; 95% CI: 1.28–1.75). Finally, wild-
type NSPC transplantation (SMD= 1.41; 95% CI: 1.18–
1.64) and induced pluripotent stem cell-derived (iPSc-derived) NSPC (SMD= 1.64; 95% CI: 0.83–2.45) had
similar eﬀects on motor function recovery.
Eﬃcacy of neural stem cell transplantation on sensory
status. Allodynia. Nine studies (Hofstetter et al.,
2005; Macias et al., 2006; Hu et al., 2010; Karimi-
Abdolrezaee et al., 2010; Salazar et al., 2010; Piltti
et al., 2013a,b; Sontag et al., 2013; Salewski et al.,
2015b) including 11 experiments evaluated NSPCs eﬃ-
cacy on allodynia among the subjects (Fig. 3). NSPC
transplantation had no signiﬁcant eﬀect on allodynia
(Pooled SMD= 0.08; 95% CI: 0.33 to 0.49; p= 0.69;
I2 = 58.4%). Study heterogeneity persuaded us to con-
duct subgroup analysis in this section as well. Since in
all these surveys female mice were also included and
intrathoracic spinal transplantation was performed, these
factors were excluded from the subgroup analyses. As
presented in Table 4, none of the evaluated factors signif-
icantly inﬂuenced NSPCs eﬃcacy on allodynia.
Hyperalgesia. Eleven surveys (Teng et al., 2002;
Hofstetter et al., 2005; Macias et al., 2006; Karimi-
Abdolrezaee et al., 2010; Luo et al., 2013; Piltti et al.,
2013a,b; van Gorp et al., 2013; Amemori et al., 2015;
Salewski et al., 2015b; Yao et al., 2015) including 16
experiments examined NSPC eﬃcacy of on hyperalgesia
(Fig. 3). Pooled analysis demonstrated that NSPC trans-
plantation had no signiﬁcant eﬀect on hyperalgesia
(Pooled SMD= 0.25; 95% CI: 0.10 to 0.60; p= 0.16;
I2 = 64.4%). However, subgroup analysis showed
improved hyperalgesia to some extent when NSPCs were
extracted from mice (SMD= 0.33; 95% CI: 0.02–0.67)
rather than rats (SMD= 0.18; 95% CI: 0.56 to 0.21)
or human (SMD= 0.37; 95% CI: 0.48 to 1.17). Trans-
plantation of more than 3  106 cell dose/kg
(SMD= 0.37; 95% CI: 0.02 to 0.77) in the ﬁrst day after
injury induction (SMD= 0.33; 95% CI: 0.02 to 0.24)
slightly improved hyperalgesia as well. Findings are pre-
sented in Table 5.
DISCUSSION
The present study, for the ﬁrst time, designed to review
the data gathered from animal models evaluating of
NSPC transplantation eﬃcacy on functional recovery
and neuropathic pain relief in SCI through a quantitative
approach. Findings conﬁrmed that NSPC transplantation
could signiﬁcantly improve motor function recovery in
the studied animals. NSPC eﬃcacy was aﬀected by the
injury model (compression, contusion, hemisection, and
transection), intervention phase, transplanted cell
number, and immunosuppressive administration.
Scaﬀold use with transplanted NSPCs could also boost
transplantation eﬃcacy. In addition, mice-derived
NSPCs were found to be considerably more eﬀective for
hyperalgesia alleviation than rat or human origin cells.
Transplanted cell numbers and intervention phase were
also reported to aﬀect hyperalgesia improvement.
Allodynia, on the other hand, was not aﬀected by NSPC
transplantation.
Reviews, on the other hand, have been reported
improvement in NSPC implantation eﬃcacy on motor
Table 2. Quality assessment of included studies
Author, year 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Abematsu et al., 2010 U U U U U U U U U U U U U U U U
Amemori et al., 2013 U U U U U U U U U U U U U U U
Amemori et al., 2015 U U U U U U U U U U U U U U U
Bottai et al., 2008 U U U U U U U U U U U U U U
Chen et al., 2010 U U U U U U U U U U U U U U U U
Cheng et al., 2012 U U U U U U U U U U U U U U U
Cummings et al., 2005 U U U U U U U U U U U U U
Cusimano et al., 2012 U U U U U U U U U U U U U U
Du et al., 2011 U U U U U U U U U U U U U U U
Fujimoto et al., 2012 U U U U U U U U U U U U U U U
Gu et al., 2012 U U U U U U U U U U U U
Guo et al., 2007 U U U U U U U U U U U U U
Guo et al., 2012 U U U U U U U U U U U U U U U
He et al., 2013 U U U U U U U U U U U U U
Hofstetter et al., 2005 U U U U U U U U U U U U U U U
Hong et al., 2014 U U U U U U U U U U U U U U U
Hooshmand et al., 2009 U U U U U U U U U U U U U U U U U U
Hu et al., 2010 U U U U U U U U U U U
Hwang et al., 2014 U U U U U U U U U U U U U U
Iwai et al., 2015 U U U U U U U U U U U U U U U
Iwanami et al., 2005 U U U U U U U U U U U U U U
Iwasaki et al., 2014 U U U U U U U U U U U U U U U U U
Johnson et al., 2010 U U U U U U U U U U U U U U
Karimi-Abdolrezaee et al., 2010 U U U U U U U U U U U U U U U U
Karimi-Abdolrezaee et al., 2006 U U U U U U U U U U U U U U U U U
Kim et al., 2011 U U U U U U U U U U U U U
Kim et al., 2012 U U U U U U U U U U U U U U
Kobayashi, 2012 U U U U U U U U U U U U U U U
Kumagai et al., 2009 U U U U U U U U U U U U U U
Kumamaru et al., 2013 U U U U U U U U U U U U U U U
Lee et al., 2009 U U U U U U U U U U U U U U
Liu et al., 2015 U U U U U U U U U U U U U U U
Lowry et al., 2008 U U U U U U U U U U U U U U
Lu et al., 2012 U U U U U U U U U U U U U U
Lu et al., 2014 U U U U U U U U U U U U U U
Luo et al., 2013 U U U U U U U U U U U U U U U U
Macias et al., 2006 U U U U U U U U U U U U U U U U
Nemati et al., 2014 U U U U U U U U U U U U U U U U
Nishimura et al., 2013 U U U U U U U U U U U U U U
Nori et al., 2011 U U U U U U U U U U U U U U U
Nutt et al., 2013 U U U U U U U U U U U U U
Okada et al., 2005 U U U U U U U U U U U U
Ormond et al., 2014 U U U U U U U U U U U U U U U U U
Pallini et al., 2005 U U U U U U U U U U U U U U
Pan et al., 2008 U U U U U U U U U U U U U U
Park et al., 2013 U U U U U U U U U U U U U U U
Parr et al., 2008a U U U U U U U U U U U U U U
Parr et al., 2008b U U U U U U U U U U U U U
Parr et al., 2007 U U U U U U U U U U U U U
Piltti et al., 2013a U U U U U U U U U U U U U U U U U
Piltti et al., 2013b U U U U U U U U U U U U U U U U U
Pomeshchik et al., 2015 U U U U U U U U U U U U U U U U U U
Romanyuk et al., 2015 U U U U U U U U U U U U U U U U
Salazar et al., 2010 U U U U U U U U U U U U U U U U U U
Salewski et al., 2015a U U U U U U U U U U U U U U U U U
Salewski et al., 2015b U U U U U U U U U U U U U U U
Sharp et al., 2014 U U U U U U U U U U U U U U U U U
Sontag et al., 2013 U U U U U U U U U U U U U U U U
Tarasenko et al., 2007 U U U U U U U U U U U U U U U
Teng et al., 2002 U U U U U U U U U U U U U U U U
Tsuji et al., 2010 U U U U U U U U U U U U U
van Gorp et al., 2013 U U U U U U U U U U U U U U U U U U
Wang et al., 2014 U U U U U U U U U U U U U U U U
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Table 2 (continued)
Author, year 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Wang et al., 2011 U U U U U U U U U U U U U U U U
Xia et al., 2013 U U U U U U U U U U U U U U U U U
Xu et al., 2011 U U U U U U U U U U U U U U U U U
Yamane et al., 2010 U U U U U U U U U U U U U U
Yang et al., 2013 U U U U U U U U U U U U U U U U
Yao et al., 2015 U U U U U U U U U U U U U U U U
Yasuda, 2011 U U U U U U U U U U U U U U U U
Yokota et al., 2015 U U U U U U U U U U U U U
Yuan et al., 2014 U U U U U U U U U U U U U U U U
Zhang et al., 2007 U U U U U U U U U U U U U U
Ziv et al., 2006 U U U U U U U U U U U U U U
1. Compliance with animal welfare regulations; 2. Statement describing control of temperature; 3. Publication in a peer-reviewed journal; 4. Description of anima; species; 5.
Designation of strain; 6. Number of animals per group; 7. Sample size calculation; 8. Present of animals’ age/weight; 9. Description of level of Injury; 10. Severity of Injury 11.
Randomly assigning animals to a speciﬁc group; 12. Allocation concealment 13. Description of the control groups; 14. Bladder expression; 15. Description of the reasons to
exclude animals from the experiment during the study (attrition); 16. Use of appropriate tests to prove hypothesis; 17. Blindness of assessor; 18. Description of statistical
analysis; 19. Statement of any potential conﬂict of interest.
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reported that most surveys have veriﬁed the positive
eﬀects of NSPC transplantation on motor function
outcomes of the evaluated animals. However, they did
not ﬁnd the optimal source of NSPCs for this purpose
(Tetzlaﬀ et al., 2011). In this regard, we performed sub-
group analysis based on donor species and NSPC embry-
onic or adult source. No signiﬁcant diﬀerences were
observed between embryonic and adult NSPC eﬀects
on motor function recovery, or neuropathic pain relief.
Mothe and Tator found relative improvements of motor
function recovery in response to NSPC transplantation
(Mothe and Tator, 2013).
Although, NSPCs are suitable sources for SCI
alleviation, ethical issues on fetal human origin tissues
and lack of autologous cell sources have limited their
uses (Mothe and Tator, 2013). Therefore, adult tissue-
derived NSPCs may be used for SCI treatment. In recent
years, alternative sources were introduced for NSPC
derivation. IPSC-derived NSPCs originated from repro-
gramed somatic cells provide an autologous source for
NSPCs without ethical concerns. In spite of experimental
studies with improved motor function recovery post iPSC-
derived NSPC transplantation in SCI cases, some studies
depicted no signiﬁcant eﬀect. The present meta-analysis
showed that both wild-type and iPSC-derived NSPCs
could drastically improve motor function recovery. Previ-
ous studies demonstrated that iPSC-derived NSPCs pro-
vide therapeutic beneﬁts via the same mechanisms as
wild-type or embryonic stem cell-derived NPSCs (Lu
et al., 2012). Transplantation of iPSC-derived NSPCs
could improve myelin repair, axon regeneration, and neu-
rotropic factors secretion while reduced secondary inﬂam-
matory responses, (Nori et al., 2011; Fujimoto et al.,
2012; Nutt et al., 2013; Romanyuk et al., 2015). There-
fore, similar eﬃcacy of the two mentioned sources of stem
cells in motor function recovery was not unexpected.
Including seven studies in their systematic review, Lee-
Kubli and Lu demonstrated promising survival, diﬀerentia-
tion and therapeutic eﬀect of iPSC-derived NSPC trans-
plantation after SCI. However, they stated that ideal
iPSC reprograming and diﬀerentiation remain unclearand need further investigation (Lee-Kubli and Lu, 2015).
Our results have reached to the conclusion as Lee-Kubli
and Lu study.
We included 12 studies in which iPSC-derived NSPCs
provoked a great eﬃcacy diﬀerences in motor function
recovery (Tsuji et al., 2010; Nori et al., 2011; Fujimoto
et al., 2012; Nutt et al., 2013; Hong et al., 2014; Lu
et al., 2014; Amemori et al., 2015; Liu et al., 2015;
Pomeshchik et al., 2015; Romanyuk et al., 2015;
Salewski et al., 2015b). One plausible reason for such
heterogeneity may be rooted in the age of somatic cell
donor (embryonic or adult). Therefore, we performed
more speciﬁc analyses, based on the iPSC embryonic
or adult somatic source. In this context, results showed
that eﬃcacy of embryonic-derived iPSCs (SMD= 1.89;
95% CI: 0.93–2.84) was considerably higher than those
with adult somatic source (SMD= 0.79; 95% CI: 0.32–
1.25). The diﬀerence may be due to adult somatic
tissue-derived iPSCs characteristics i.e., the cells dis-
played signiﬁcant resistance to diﬀerentiation (Tsuji
et al., 2011). Mothe and Tator, stated that adult human
NSPCs were diﬃcult to expand for suﬃcient cell trans-
plantation. They also added that iPSCs could trigger T-
cell induced immune response in syngeneic recipients
(Mothe and Tator, 2013). Moreover, adult tissue-derived
iPSCs were not as safe as embryonic-derived clones
which, could form teratoma in SCI implantation (Tsuji
et al., 2011). However, our current knowledge regarding
iPSC-derived NSPC tumorigenicity, safety, and alterna-
tive reprograming is still insuﬃcient.
Motor function recovery post NSPC transplantation is
generally aﬀected by intervention phase. Findings
revealed that a shorter time gap between injury
induction and transplantation could improve the
eﬃciency of the treatment. Accordingly, transplantation
during acute and sub-acute phases is associated with
better results compared to chronic phase. This might be
due to the partial irreversible nature of the injuries in
chronic phase (Oyinbo, 2011). Similar eﬃcacy of the
acute and sub-acute phases has been the notable ﬁnding
among the studies. This is incongruent with the current
assumption, since acute phase inﬂammatory responses
NOTE: Weights are from random effects analysis
Overall  (I−squared = 81.0%, p = 0.000)
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1.40 (0.25, 2.55)
1.43 (0.54, 2.31)
1.10 (0.26, 1.93)
1.95 (1.07, 2.83)
1.17 (0.02, 2.31)
5.33 (3.38, 7.27)
7.48 (5.13, 9.83)
0.60 (−0.30, 1.50)
3.51 (1.60, 5.42)
1.18 (0.58, 1.78)
1.34 (0.36, 2.32)
−0.01 (−1.10, 1.08)
4.70 (3.16, 6.24)
1.01 (0.14, 1.89)
0.02 (−0.85, 0.88)
3.42 (1.61, 5.24)
1.70 (0.66, 2.74)
0.50 (−0.58, 1.58)
1.23 (0.26, 2.19)
0.37 (−0.48, 1.21)
1.58 (0.51, 2.66)
−0.08 (−1.23, 1.07)
2.61 (1.79, 3.43)
−0.92 (−1.81, −0.04)
0.42 (−0.58, 1.41)
−0.12 (−1.10, 0.86)
−0.91 (−1.83, 0.02)
1.42 (0.43, 2.42)
3.02 (1.42, 4.62)
2.61 (1.00, 4.22)
1.24 (−0.14, 2.62)
−0.11 (−0.95, 0.73)
0.63 (0.13, 1.13)
1.11 (0.40, 1.82)
1.08 (−0.77, 2.94)
5.70 (4.03, 7.38)
0.45 (−0.13, 1.03)
4.80 (3.32, 6.29)
1.26 (0.18, 2.35)
1.78 (0.60, 2.96)
2.43 (1.25, 3.61)
−0.22 (−0.99, 0.55)
1.26 (0.30, 2.23)
1.14 (0.03, 2.24)
1.39 (0.29, 2.50)
2.40 (0.86, 3.95)
−0.03 (−0.83, 0.77)
7.78 (4.73, 10.82)
0.07 (−0.73, 0.86)
3.67 (2.10, 5.24)
0.04 (−0.80, 0.87)
0.00 (−0.86, 0.86)
0.68 (−0.41, 1.78)
0.28 (−0.53, 1.10)
SMD (95% CI)
0.98 (−0.29, 2.25)
−1.13 (−1.98, −0.28)
0.00 (−1.29, 1.29)
1.04 (0.21, 1.86)
0.53 (−0.41, 1.47)
2.51 (1.31, 3.71)
2.96 (1.66, 4.27)
1.64 (0.49, 2.79)
0.45 (−0.70, 1.60)
1.57 (0.02, 3.12)
1.00 (−0.08, 2.09)
3.08 (1.75, 4.42)
3.59 (1.81, 5.37)
1.65 (0.81, 2.49)
−0.23 (−1.03, 0.58)
1.40 (0.48, 2.32)
1.32 (−0.08, 2.71)
3.04 (1.28, 4.80)
1.57 (0.50, 2.64)
2.30 (1.20, 3.40)
2.34 (1.17, 3.50)
4.97 (3.01, 6.92)
1.44 (0.21, 2.68)
1.02 (−0.15, 2.20)
1.42 (0.52, 2.33)
1.01 (−0.04, 2.06)
1.58 (0.36, 2.81)
1.28 (0.10, 2.46)
3.25 (1.23, 5.27)
2.32 (1.16, 3.48)
2.49 (0.51, 4.47)
0.83 (−0.15, 1.80)
0.15 (−0.64, 0.93)
0.00 (−0.77, 0.77)
1.24 (0.42, 2.07)
0.53 (−0.15, 1.21)
4.12 (2.90, 5.33)
0.12 (−0.57, 0.82)
1.30 (−0.11, 2.72)
−0.13 (−1.14, 0.89)
0.98 (0.13, 1.83)
1.95 (1.07, 2.83)
2.06 (0.95, 3.16)
4.42 (2.98, 5.86)
1.04 (0.18, 1.91)
3.20 (1.71, 4.69)
1.42 (0.52, 2.33)
0.14 (−1.01, 1.29)
0−18.2 18.2
Fig. 2. Eﬃcacy of neural stem/progenitor cells transplantation on motor function recovery after spinal cord injury. This method signiﬁcantly
improved functional recovery.
386 M. Youseﬁfard et al. / Neuroscience 322 (2016) 377–397creates a cytotoxic environment, which is incompatible
with the NSPC survival and diﬀerentiation and focuses
on better results of the cell therapy in sub-acute phasethan acute and chronic phases (Mothe and Tator,
2013). The present study showed that treatment in the
acute phase had even slightly higher eﬃcacy than sub-
Table 3. Subgroup analyses of the eﬀect of neural stem/progenitor cells on functional recovery
Characteristic P for biasa Model P (I2)b Eﬀect size c (95% CI) P
Gender
Male 0.93 REM <0.001 (80.3%) 1.91 (1.37–2.45) <0.001
Female 0.43 REM <0.001 (80.9%) 1.35 (1.10–1.56) <0.001
Overall signiﬁcance test among subgroups 0.14
Recipient species
Mice 0.05 REM <0.001 (85.1%) 1.68 (1.27–2.09) <0.001
Rat 0.17 REM <0.001 (78.9%) 1.30 (1.03–1.58) <0.001
Other 0.45 FEM 0.12 (42.3%) 1.48 (0.64–2.31) <0.001
Overall signiﬁcance test among subgroups 0.42
Injury model
Contusion 0.92 REM <0.001 (81.7%) 1.54 (1.23–1.86) <0.001
Clip compression 0.44 REM 0.001 (61.4%) 0.58 (0.16–0.99) 0.007
Balloon compression 0.31 REM 0.04 (63.9%) 1.88 (1.11–2.64) <0.001
Hemisection 0.49 REM 0.004 (57.4%) 1.10 (0.69–1.51) <0.001
Transection 0.44 REM <0.001 (88.1%) 2.18 (1.45–2.93) <0.001
Overall signiﬁcance test among subgroups 0.045
Location of injury
Cervical 0.13 FEM 0.20 (28.3%) 0.54 (0.05–1.03) 0.03
Thoracic 0.52 REM <0.001 (81.9%) 1.52 (1.28–1.75) <0.001
Lumbar NA NA NA NA NA
Overall signiﬁcance test among subgroups 0.054
Severity of injury
Mild NA NA NA NA NA
Moderate 0.61 REM <0.001 (80.0%) 1.28 (0.99–1.57) <0.001
Severe 0.59 REM <0.001 (82.5%) 1.70 (1.33–2.06) <0.001
Overall signiﬁcance test among subgroups 0.17
Stem cells derivation origin
Brain 0.65 REM <0.001 (81.7%) 1.50 (1.24–1.77) <0.001
Spine 0.06 REM <0.001 (71.1%) 1.51 (1.03–1.98) <0.001
Other 0.81 REM <0.001 (89.6%) 1.64 (0.83–2.45) <0.001
Overall signiﬁcance test among subgroups 0.39
Cell type
wt-NSPCs 0.74 REM <0.001 (78.5%) 1.41 (1.18–1.64) <0.001
iPSC-NSPCs 0.81 REM <0.001 (89.6%) 1.64 (0.83–2.45) <0.001
Overall signiﬁcance test among subgroups 0.75
Intervention phased
Acute 0.20 REM <0.001 (82.8%) 1.80 (1.36–2.24) <0.001
Subacute 0.79 REM <0.001 (83.2%) 1.38 (1.08–1.67) <0.001
Chronic 0.90 REM <0.001 (75.1%) 1.04 (0.47–1.60) <0.001
Overall signiﬁcance test among subgroups 0.044
Delivery route
Intra spinal 0.65 REM <0.001 (81.5%) 1.42 (1.19–1.66) <0.001
Other 0.92 REM <0.001 (74.9%) 1.88 (1.04–2.71) <0.001
Overall signiﬁcance test among subgroups 0.43
Graft type
Allogeneic 0.35 REM <0.001 (83.3%) 1.66 (1.35–1.97) <0.001
Xenogeneic 0.02 REM <0.001 (75.1%) 1.13 (0.81–1.44) <0.001
Overall signiﬁcance test among subgroups 0.10
Number of transplanted cells
<3  106 cell dose/kg 0.92 REM <0.001 (64.5%) 0.94 (0.67–1.22) <0.001
P3  106 cell dose/kg 0.13 REM <0.001 (84.3%) 1.74 (1.43–2.05) <0.001
‘ Overall signiﬁcance test among subgroups 0.02
Donor species
Mice 0.54 REM <0.001 (83.1%) 1.48 (1.13–1.83) <0.001
Rat 0.06 REM <0.001 (83.3%) 1.53 (1.10–1.97) <0.001
Human 0.39 REM <0.001 (76.5%) 1.33 (0.89–1.76) <0.001
Other 0.73 FEM 0.72 (0.0%) 1.61 (0.79–2.44) <0.001
Overall signiﬁcance test among subgroups 0.82
(continued on next page)
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Table 3 (continued)
Characteristic P for biasa Model P (I2)b Eﬀect size c (95% CI) P
Donor age
Fetal 0.37 REM <0.001 (78.7%) 1.60 (1.33–1.87) <0.001
Newborn >0.99 REM <0.001 (71.8%) 1.32 (0.64–2.00) <0.001
Adult 0.90 REM <0.001 (84.3%) 1.14 (0.69–1.59) <0.001
Overall signiﬁcance test among subgroups 0.20
Use of co-treatment
No 0.99 REM <0.001 (81.2%) 1.36 (1.10–1.62) <0.001
Scaﬀold 0.84 REM <0.001 (82.2%) 2.19 (1.30–2.07) <0.001
SC cells or BMMSC 0.60 REM <0.001 (88.9%) 1.21 (0.24 to 2.65) 0.10
Growth factors 0.12 REM <0.001 (85.6%) 0.93 (0.22 to 2.08) 0.11
Other 0.002 REM <0.001 (78.9%) 1.79 (1.16–2.41) <0.001
Overall signiﬁcance test among subgroups 0.72
Use of antibiotic
No 0.17 REM <0.001 (77.9%) 1.24 (0.98–1.51) <0.001
Yes 0.56 REM <0.001 (84.0%) 1.77 (1.37–2.16) <0.001
Overall signiﬁcance test among subgroups 0.11
Use of immunosuppressive agents
No 0.94 REM <0.001 (82.7%) 1.80 (1.49–2.10) <0.001
Yes 0.49 REM <0.001 (72.4%) 0.87 (0.57–1.17) <0.001
Overall signiﬁcance test among subgroups 0.003
Blinding of observer
No 0.74 REM <0.001 (67.7%) 1.34 (0.85–1.84) <0.001
Yes 0.85 REM <0.001 (82.3%) 1.48 (1.23–1.73) <0.001
Overall signiﬁcance test among subgroups 0.82
Follow up period
<8 weeks 0.003 REM <0.001 (81.6%) 1.49 (1.14–1.84) <0.001
P8 weeks 0.69 REM <0.001 (80.9%) 1.42 (1.21–1.72) <0.001
Overall signiﬁcance test among subgroups 0.96
Subacut: 3–10 days after injury; Chronic: equal or more than 14 days. REM: random eﬀect model; FEM: ﬁxed eﬀect, CI: conﬁdence interval; NA: not applicable because of
low number of included studies; wt-NSPCS: wild type neural stem/progenitor cells; iPSC-NSPCs: induced pluripotent stem cell-derived neural stem cells.
a Publication bias based on Begg’s and Egger’s test.
b Heterogeneity among studies.
c Standardized mean diﬀerence.
d Acute: immediately after injury.
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stem cells at the lesion site post injury can slow down
inﬂammatory processes and decrease neural deaths.
Various studies have shown neural stem cell modulatory
eﬀects on inﬂammatory/immune responses (Lee et al.,
2008a,b; Bacigaluppi et al., 2009; Ottoboni et al., 2015).
This is also rather compatible with our previous meta-
analysis in which we showed higher eﬃciencies of bone
marrow derived mesenchymal cell transplantation in neu-
ropathic pain relief after SCI if the procedure carries out
during the ﬁrst 4 days of injury (Hosseini et al., 2015).
In the present meta-analysis, we found that the NSPC
transplantation eﬃcacy varied based on the injury
induction model i.e. clip compression eﬃcacy has found
to be lower than the transection model. Diﬀerent
inﬂammatory processes seem to be the plausible
explanation for this observation. In the transection
model, the inﬂammatory processes are not activated in
the ﬁrst 12 h post injury and the nervous tissue is still
viable at the edges of the cut point (Kao and chang,
1977) and NSPC transplantation can suspend inﬂamma-
tory activation at the time. Yet, cell seeding has also beendone using a scaﬀold in most of these surveys. In the
compression model however, the inﬂammatory processes
are activated from the ﬁrst or second hour post-injury and
the function and survival of the transplanted cells should
be aﬀected accordingly. Despite rare complete transec-
tion injuries in human, compression and contusion injuries
are more prevalent (Bunge et al., 1993). Therefore, cau-
tion should be taken if clinical trials with NSPCs are
designed.
Due to major discrepancies, the optimum number of
transplanted cells is still a matter of debate. Median
number of the cells per kilograms of animal’s body
weight was 4.3  106 (interquartile range = 1.1  106–
2  107). In the present study, the 3  106 cell dose/kg
cut-oﬀ point was chosen based on some clinical
situations (Hosseini et al., 2015). Higher doses have
shown to provoke better functional recovery (Hosseini
et al., 2015). This could be due to NSPC survival chance
at higher doses eﬃcient connections in the injured tissue.
Surprisingly, immunosuppressive administration has
shown to decrease the eﬃcacy in transplanted NSPC
functional recovery after SCI (SMD= 0.79 vs.
Fig. 3. Eﬃcacy of neural stem/progenitor cells transplantation on allodynia (A) and hyperalgesia (B) after spinal cord injury. Neural stem/progenitor
cells transplantation had no signiﬁcant eﬀect on allodynia and hyperalgesia.
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Most in vivo and in vitro studies have shown inhibitory
eﬀects of immunosuppressive medications on
transplantation rejection and its facilitative inﬂuence on
cell survival. Moreover, these agents can decrease
inﬂammatory responses activated by traumatic spinal
injury and increases growth and axon branching speed
at the lesion site (Madsen et al., 1998; Xu et al., 1998).
Immunosuppressive drug inhibitory eﬀects on functional
recovery might be due to their negative eﬀects on wound
and spinal cord healing (Park et al., 2013). However,
we did not observe signiﬁcant association betweenimmunosuppressive use and eﬃcacy of bone marrow
derived stem cell transplantation with neuropathic pain
relief after SCI (Hosseini et al., 2015). These ﬁndings
are indicative of the need for further investigations on this
matter.
The role of NSPC transplantation in neuropathic pain
relief was another subject of this study. Analyses
showed that NSPC transplantation could relieve
hyperalgesia without any eﬀect on allodynia. Eaton in
his study showed that neural cell lines could alleviate
neuropathic pains (Eaton, 2004). He only included those
surveys with genetically engineered cell lines capable of
Table 4. Subgroup analyses of the eﬀect of neural stem/progenitor cells on allodynia
Characteristic P for biasa Model P (I2)b Eﬀect Size c (95% CI) P
Recipient species
Mice 0.50 FEM 0.07 (48.6%) 0.65 (0.27 to 1.57) 0.16
Rat 0.55 FEM 0.05 (60.9%) 0.13 (0.54 to 0.28) 0.53
Overall signiﬁcance test among subgroups 0.18
Injury model
Contusion 0.91 REM 0.003 (68.1%) 0.08 (0.49 to 0.64) 0.80
Compression 0.12 FEM 0.96 (0.0%) 0.27 (0.21 ti 0.69) 0.39
Overall signiﬁcance test among subgroups 0.55
Severity of injury
Moderate 0.46 REM 0.001 (70.2%) 0.16 (0.43 to 0.76) 0.60
Severe 0.30 FEM 0.96 (0.0%) 0.05 (0.41 to 0.51) 0.84
Overall signiﬁcance test among subgroups 0.96
Stem cells derivation origin
Brain 0.72 FEM 0.12 (36.5%) 0.13 (0.38 to 0.12) 0.31
Other NA NA NA NA NA
Overall signiﬁcance test among subgroups NA
Intervention phased
Acute 0.11 REM <0.001 (93.1%) 1.14 (3.27 to 5.55) 0.62
Subacute 0.37 FEM 0.99 (0.0%) 0.12 (0.25 to 0.49) 0.49
Chronic 0.60 FEM 0.98 (0.0%) 0.16 (0.30 to 0.63) 0.54
Overall signiﬁcance test among subgroups 0.44
Graft type
Allogeneic 0.60 REM <0.001 (88.8%) 0.62 (1.22 to 2.45) 0.51
Xenogeneic 0.54 FEM 0.99 (0.0%) 0.12 (0.18 to 0.42) 0.44
Overall signiﬁcance test among subgroups 0.46
Number of transplanted cells
<3  106 cell dose/kg 0.55 REM 0.07 (48.6%) 0.13 (0.54 to 0.28) 0.53
P3  106 cell dose/kg 0.50 REM 0.05 (60.9%) 0.65 (0.27 to 1.57) 0.17
Overall signiﬁcance test among subgroups 0.18
Donor species
Mice 0.49 REM 0.01 (64.0%) 0.51 (0.40 to 1.43) 0.27
Rat NA NA NA NA NA
Human 0.38 FEM 0.99 (0.0%) 0.13 (0.22 to 0.49) 0.46
Overall signiﬁcance test among subgroups 0.79
Donor age
Fetal 0.009 FEM 0.99 (0.0%) 0.13 (0.22 to 0.49) 0.46
Newborn NA NA NA NA NA
Adult 0.49 REM <0.001 (85.3%) 0.29 (0.82 to 1.40) 0.69
Overall signiﬁcance test among subgroups 0.38
Use of co-treatment
No 0.46 REM 0.003 (88.0%) 0.09 (0.42 to 0.60) 0.73
Yes NA NA NA NA NA
Overall signiﬁcance test among subgroups 0.79
Use of antibiotic
No 0.50 REM <0.001 (85.3%) 0.46 (0.85 to 1.76) 0.49
Yes 0.55 FEM 0.99 (0.0%) 0.10 (0.22 to 0.41) 0.56
Overall signiﬁcance test among subgroups 0.22
Use of immunosuppressive agents
No 0.81 REM <0.001 (88.4%) 0.50 (1.20 to 2.2) 0.56
Yes 0.34 FEM 0.99 (0.0%) 0.08 (0.33 to 0.49) 0.38
Overall signiﬁcance test among subgroups 0.32
Blinding of observer
No NA NA NA NA NA
Yes 0.81 FEM 0.12 (36.5%) 0.05 (0.38 to 0.28) 0.78
Overall signiﬁcance test among subgroups NA
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Table 4 (continued)
Characteristic P for biasa Model P (I2)b Eﬀect Size c (95% CI) P
Follow up period
<8 weeks 0.50 REM 0.047 (62.4%) 0.56 (0.28 to 1.39) 0.19
P8 weeks 0.55 REM 0.08 (47.3%) 0.14 (0.57 to 0.29) 0.53
Overall signiﬁcance test among subgroups 0.21
Subacut: 3–10 days after injury; Chronic: equal or more than 14 days; REM: random eﬀect model; FEM: ﬁxed eﬀect, CI: conﬁdence interval; NA: not applicable because of
low number of included studies.
a Publication bias based on Begg’s and Egger’s test.
b Heterogeneity among studies.
c Standardized mean diﬀerence.
d Acute: immediately after injury.
Table 5. Subgroup analyses of the eﬀect of neural stem/progenitor cells on hyperalgesia
Characteristic P for biasa Model P (I2)b Eﬀect Size c (95% CI) P
Gender
Male 0.30 FEM 0.19 (39.8%) 0.05 (0.50 to 0.40) 0.81
Female 0.84 REM <0.001 (68.2%) 0.34 (0.07 to 0.75) 0.94
Overall signiﬁcance test among subgroups 0.44
Recipient species
Rat 0.14 REM <0.001 (66.7%) 0.26 (0.10 to 0.63) 0.16
Other NA NA NA NA NA
Overall signiﬁcance test among subgroups NA
Injury model
Contusion 0.33 FEM 0.74 (0.0%) 0.18 (0.50 to 0.14) 0.29
Clip compression 0.17 REM <0.001 (86.1%) 0.96 (0.29 to 2.22) 0.13
Balloon compression NA NA NA NA NA
Hemisection NA NA NA NA NA
Transection 0.60 REM <0.001 (65.8%) 0.06 (0.37 to 0.50) 0.77
Overall signiﬁcance test among subgroups 0.64
Location of injury
Thoracic 0.44 FEM 0.28 (15.3%) 0.07 (0.13 to 0.27) 0.50
Lumbar NA NA NA NA NA
Overall signiﬁcance test among subgroups NA
Severity of injury
Moderate 0.18 REM <0.001 (83.5%) 0.34 (0.32 to 0.99) 0.31
Severe 0.80 FEM 0.34 (9.6%) 0.20 (0.10 to 0.50) 0.19
Overall signiﬁcance test among subgroups 0.84
Stem cells derivation origin
Brain 0.54 FEM 0.38 (6.9%) 0.10 (0.12 to 0.32) 0.12
Spine NA NA NA NA NA
Lung NA NA NA NA NA
Overall signiﬁcance test among subgroups NA
Cell type
wt-NSPCs 0.58 REM <0.001 (65.8%) 0.30 (0.07 to 0.67) 0.11
iPSC-NSPCs NA NA NA NA NA
Overall signiﬁcance test among subgroups NA
Intervention phased
Acute 0.99 FEM 0.27 (22.6%) 0.33 (0.02 to 0.24) 0.07
Subacute 0.99 REM <0.001 (76.3%) 0.20 (0.38 to 0.79) 0.38
Chronic NA NA NA NA NA
Overall signiﬁcance test among subgroups 0.89
Delivery route
Intra spinal 0.32 REM <0.001 (66.4%) 0.24 (0.12 to 0.61) 0.20
Other NA NA NA NA NA
Overall signiﬁcance test among subgroups NA
(continued on next page)
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Table 5 (continued)
Characteristic P for biasa Model P (I2)b Eﬀect Size c (95% CI) P
Graft type
Allogeneic 0.25 FEM 0.50 (0.0%) 0.15 (0.51 to 0.21) 0.43
Xenogeneic 0.73 REM <0.001 (69.3%) 0.37 (0.08 to 0.81) 0.10
Overall signiﬁcance test among subgroups 0.40
Number of transplanted cells
<3  106 cell dose/kg 0.73 REM <0.001 (69.7%) 0.20 (0.24 to 0.64) 0.37
P3  106 cell dose/kg 0.16 FEM 0.26 (25.5%) 0.37 (0.02 to 0.77) 0.06
Overall signiﬁcance test among subgroups 0.65
Donor species
Mice 0.33 FEM 0.40 (1.8%) 0.33 (0.02–0.65) 0.04
Rat 0.53 FEM 0.33 (9.9%) 0.18 (0.56 to 0.21) 0.36
Human 0.99 REM <0.001 (80.4%) 0.37 (0.48 to 1.17) 0.28
Overall signiﬁcance test among subgroups 0.47
Donor age
Fetal 0.33 REM <0.001 (81.3%) 0.47 (0.35 to 1.29) 0.26
Newborn 0.19 FEM 0.27 (22.9%) 0.56 (0.07–1.05) 0.03
Adult 0.30 FEM 0.22 (27.5%) 0.04 (0.33 to 0.25) 0.78
Overall signiﬁcance test among subgroups 0.43
Use of co-treatment
No 0.21 REM <0.001 (74.0%) 0.25 (0.20 to 0.70) 0.28
Yes 0.73 FEM 0.41 (0.0%) 0.30 (0.10 to 0.71) 0.15
Overall signiﬁcance test among subgroups 0.90
Use of antibiotic
No 0.42 REM 0.03 (67.3%) 0.29 (0.38 to 0.97) 0.40
Yes 0.16 REM 0.001 (66.5%) 0.25 (0.19 to 0.67) 0.27
Overall signiﬁcance test among subgroups 0.72
Use of immunosuppressive agents
No 0.53 REM 0.03 (67.5%) 0.25 (0.34 to 0.85) 0.40
Yes 0.21 REM 0.001 (66.3%) 0.25 (0.18 to 0.70) 0.27
Overall signiﬁcance test among subgroups 0.97
Blinding of observer
No NA NA NA NA NA
Yes 0.54 REM <0.001 (66.6%) 0.27 (0.10 to 0.65) 0.94
Overall signiﬁcance test among subgroups NA
Follow up period
>8 weeks 0.14 FEM 0.72 (0.0%) 0.16 (0.18 to 0.51) 0.36
P8 weeks 0.62 REM <0.001 (75.0%) 0.32 (0.20 to 0.83) 0.23
Overall signiﬁcance test among subgroups 0.30
Subacut: 3–10 days after injury; Chronic: equal or more than 14 days. REM: random eﬀect model; FEM: ﬁxed eﬀect, CI: conﬁdence interval; NA: not applicable because of
low number of included studies; wt-NSPCS: wild type neural stem/progenitor cells; iPSC-NSPCs: induced pluripotent stem cell-derived neural stem cells.
a Publication bias based on Begg’s and Egger’s test.
b Heterogeneity among studies.
c Standardized mean diﬀerence.
d Acute: immediately after injury.
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immortalized cell lines used for neuropathic pain relief,
rather than neural stem cells. Secretion of anti-
nociceptive mediators such as met-enkephalin, gamma-
aminobutyric acid (GABA), and opioids can attenuate
neuropathic pain symptoms. That would be the reason
for the discrepant results of the two studies Furthermore,
Franchi et al. in their narrative review referred to the neu-
ral stem cells as the suitable sources for neural regener-
ation and neuropathic pain relief (Franchi et al., 2014).
In spite of our study that addresses central models, Fran-
chi et al mainly focuses the chronic construction of the sci-atic nerve model with a peripheral aspect suitable for
neural injuries induction. Referring to the diﬀerent mecha-
nisms of peripheral and central pain models (Burnett and
Zager, 2004; Scholz and Woolf, 2007; Oyinbo, 2011), this
controversy is predictable.
According to Li and Lepski neural stem cell
transplantation has no signiﬁcant eﬀect on sensory
status after SCIs (Li and Lepski, 2013). This might be
due to the neural stem cell high tendency for glial cell dif-
ferentiation. Some studies have a diﬀerentiation rate of
40% to glial cells post transplantation compared with
much less rate for neuronal diﬀerentiation (Tarasenko
M. Youseﬁfard et al. / Neuroscience 322 (2016) 377–397 393et al., 2007). These changes might exacerbate secondary
injuries developed within the ﬁrst hours post SCI and can
persist through months or sometimes years after the
insult (Rowland et al., 2008).
In our previous meta-analysis (Hosseini et al., 2015),
we showed that bone marrow-derived mesenchymal stem
cell implantation could improve allodynia with no signiﬁ-
cant eﬀects on hyperalgesia unless it was implanted dur-
ing the acute phase of injury. Mesenchymal stem cells
could attenuate most unfavorable acute and chronic dam-
ages in the injured spinal cord (Wright et al., 2007;
Teixeira et al., 2013). Implanted cells have a neuroprotec-
tive role (Uccelli et al., 2008) and can reduce pro-
inﬂammatory cytokines, reactive oxygen species, and
asteriogliosis (Abrams et al., 2009). These cells can also
enhance host neural stem cell to oligodendrocytes diﬀer-
entiation and stimulate re-myelination (Rivera et al.,
2006). However, NSPCs have less immunomodulatory
properties and are apt to diﬀerentiate into astrocytes.
Since NSPCs can develop some degree of allodynia
and hyperalgesia in SCI animals (Hofstetter et al., 2005;
Macias et al., 2006), their transplantation cannot signiﬁ-
cantly improve allodynia and hyperalgesia in the SCI
animal models. According to Mothe and Tator, only pre-
diﬀerentiated NSPCs grafts in astrocytes can improve
allodynia (Mothe and Tator, 2013).
Finally, subgroup analysis showedmore improvements
in hyperalgesia when NSPCs were extracted from mice
rather than rats or human. Several reasons are required
to explain this phenomenon. According to Mothe and
Tator human derived NSPCs were either unavailable or
diﬃcult to grow (Mothe and Tator, 2013). In addition, Druk-
ker and Benvenisty showed that human-derived NSPCs
rejection imposed a great threat to their clinical use in
regenerative medicine (Drukker and Benvenisty, 2004).
In contrast, mouse NSPCs are a non-immunogenic
immune-privileged tissue, and can be transplanted into
allogeneic recipients without immunosuppressive regi-
mens side eﬀects (Hori et al., 2003).
STRENGTHS AND LIMITATIONS
In the present study, extended electronic search, authors
contact, and manual webpage search were used to
include maximum number of articles and gray literature.
This method provided us with 74 studies and 125
experiments in the meta-analysis. Accordingly, data
from 2382 animal subjects were pooled together and
then analyzed. Absence of publication bias was one of
the strengths of this survey. Heterogeneity in analyses
was one of the study limitations, which was overcome
through subgroup analysis. Lack of observers blinded to
some included studies was another limitation. However,
since in subgroup analysis neutrality is irrelevant to
NSPCs transplantation eﬃcacy on functional recovery
and sensory condition, bias would accordingly be at its
minimum levels.
CONCLUSION
Findings of the present meta-analysis showed that the
eﬃcacy of NSPC transplantation depends on the injurymodel, intervention phase, number of transplanted cells,
immunosuppressive medications, and probably the cell
source. The eﬃcacy of this treatment method is higher
in transection and contusion injury models than
compression one. The shorter the interval between
injury and treatment, led to the better the functional
recovery and sensory condition. The best treatment
dose was also found to be higher than 3  106 cell
dose/kg. Immunosuppressive drug administration was
found to negatively aﬀect motor function recovery.
Scaﬀold use could also boost NSPC eﬃcacy on motor
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